Virbac UK Veterinary
Caution, This content is for veterinary professionals.

Alizin®

For the treatment of canine misalliance

Aglepristone is a synthetic progesterone antagonist, effective on uterine progesterone receptors, with a relative binding affinity three times stronger than endogenous progesterone, providing effective competitive antagonism of progesterone and blocking the hormone responsible for implantation and pregnancy maintenance

Product Features & Benefits: 

  • High efficacy over a flexible treatment period from 0 to 45 days post-mating

  • Two doses 24 hours apart (timing is important in its success)

  • Given by subcutaneous injection, at 1ml / 3kg, using a maximum of 5ml per injection site

  • Excellent safety profile

 

Presentations Available: 

10ml vial

 

Product FAQ

  • 1. What is Alizin?

    Alizin contains Aglepristone, a progesterone receptor antagonist that blocks the hormone needed for implantation and placental development, causing abortion within a few days of the course.

  • 2. When can Alizin be used?

    Alizin is authorised to induce abortion from day 1 to 45 post mating although we recommend waiting to the end of oestrus before using the product to avoid the need for repeat courses. This is usually 10 to 14 days post mating.

  • 3. What is the efficacy?

    In the first trimester (up to day 21) the efficacy is 99.9%. In the second trimester the aglepristone acts on placental development and efficacy is 95%.

  • 4. What is the dose rate?

    The dose is 10mg/kg and the concentration of the vial is 30mg per ml.

  • 5. When does the abortion process start and finish?

    The abortion process will start within a few days and be completed by 7 days.

  • 6. What happens in partial or where no abortion occurs?

    In case of partial abortion or no abortion, repeat treatment may be recommended 10 days after treatment, between day 30 and day 45 after mating. Surgery should also be considered.

  • 7. Is Alizin a mutagen or teratogen?

    There is no evidence that aglepristone causes mutations or congenital abnormalities.